Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
There's a simple explanation why Druckenmiller likes Revolution Medicines -- and why the stock has performed so well. Revolution appears to have one of the most promising pancreatic cancer therapies ...
CHICAGO, May 31 (Reuters) - Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could resume ...
Revolution Medicines Inc. RVMD, on Sunday, unveiled breakthrough data showing its experimental pancreatic cancer pill more than doubled median overall survival compared with chemotherapy in a pivotal ...
Imec teamed up with the KU Leuven laboratory of tumor immunology and immunotherapy for the first clinical validation of its cell sorter chip technology. The chip successfully identified PD-1 positive ...
Revolution Medicines, Inc. (NASDAQ:RVMD) on Sunday announced new clinical data for zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, as monotherapy in patients with KRAS G12D mutant ...
(MENAFN- GlobeNewsWire - Nasdaq) REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results